Biosyntech Inc. reported earnings results for the second quarter and six months ended September 30, 2009. For the quarter, the company had revenues of $120,512 compared to revenues of nil for the three-month period ended September 30, 2008. The net loss for the three-month period amounted to $3,624,041 or $0.03 per share, compared to $3,015,372 or $0.03 per share for the three-month period ended September 30, 2008. For the six months, the company had revenues of $175,492 compared to revenues of $12,368 for the six-month period ended September 30, 2008. The increases in revenues were mainly due to the sale of instrumentation product (Mach-1), a non-core product for the company, during the quarter ended September 30, 2009. The loss for the six-month period amounted to $6,283,785 or $0.06 per share, compared $5,351,616 or $0.06 per share for the six-month period ended September 30, 2008.

Biosyntech Inc. reported consolidated unaudited cash flow results for the second quarter and six months ended September 30, 2009. For the quarter, cash flows used in operating activities was CAD 2.01 million against CAD 2.55 million a year ago. For the nine months, cash flows used in operating activities was CAD 3.92 million against CAD 4.43 million a year ago.

Biosyntech Inc. has appointed two additional members to its Board of Directors, Mr. André Archimbaud and Ms. Jeanne Bertonis, Chief Executive Officer for BioSyntech. Mr. Archimbaud will serve as Chairman of the Board. The company also announced that Dr. Matthew Shive, former Chief Scientific Officer of BioSyntech, has been retained as a consultant to Company.